Vitamin E and gene interactions

Similar documents
Has the science of supplementation reached the breakthrough point?

Nutrigenomics and Personalised Nutrition. John Hesketh

Nutritional ingredients for health and well-being perspectives and challenges

Why Use Genetic Testing in Practice?

Vitamin E: the latest science 2016

April Angela Walker. This is only a preview. The number of pages displayed is limited.

Regence. Medical Policy Manual. Date of Origin: May Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment

Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease

Detox and Methylation Mutation Report for Customer: a-97dd-6604ce662da3

Cognitive, affective, & social neuroscience

10/19/2017. How Nutritional Genomics Affects You in Nutrition Research and Practice Joyanna Hansen, PhD, RD & Kristin Guertin, PhD, MPH

European Journal of Internal Medicine

Facts on Fats. Ronald P. Mensink

Where are we heading?

Detox and Methylation Mutation Report for Customer: f21c5b7c-d7e5-4fae-969c-5e

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center

CardioGenomicPlus Profile

Dietary omega-3 fatty acids and risk of type-2 diabetes: Lack of antioxidants?

Dietary Supplements and Health: Hype vs. Evidence

Reactivity and Biological Functions of Oxidized Lipids

THE TRUTH ABOUT THE VITAL STUDY ON OMEGA-3 and VITAMIN D

Genetic testing in cardiovascular disease Atul K. Sachdev, MD

Structure of G6PD. Glucose-6-Phosphate Dehydrogenase (G6PD) and Malaria. Function of G6PD. Familial Genetics of G6PD. Mendelian Transmission

Early Origins of Metabolic Disease and Aging

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

Lipid Markers. Independent Risk Factors. Insulin Resistance Score by Lipid Fractionation

Cardiovascular Outcome

Nutrigenetics Building a Platform for Dietitians to Offer Personalized Nutrition By Megan D. Baumler, PhD, RD, CD

Scope of the talk. Riboflavin, other dairy B vitamins and cardiovascular health. Epidemiology of milk consumption and CVD

Novel Genetic Approach for the Identification of Placebo Responders A Viable Strategy for Reducing Clinical Trial Size, Cost and Time to Market

Reactive Oxygen species ROS + Anti-oxidants. Dr. Naif Karadsheh

Nutrition and Health Benefits of Rice Bran Oil. Dr. B. Sesikeran, MD, FAMS Former Director National Institute of Nutrition (ICMR) Hyderabad

Welcome! Mark May 14, Sat!

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Age-related hypertension is there a role for Omega 3 fatty acids in prevention and adjunctive therapy?

Individualising the Diet for Obesity based on Genetic Testing

Pharmacogenetics in: Primary Care. Bradley T. Wajda D.O.

The COSMOS Trial. (COcoa Supplement and Multivitamins Outcomes Study) JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH

JAMA. 2011;305(24): Nora A. Kalagi, MSc

A critical review of the antioxidant controversy/safety issues for fatsoluble

Estrogen Report GENOTYPE REPORT OPTIMAL HEALTH FOR LIFE. John Doe NAME DATE OF BIRTH 7/31/1999 REFFERRING PRACTITIONER. Dr. Exercise/Diet specialist

A Proposed Randomized Trial of Cocoa Flavanols and Multivitamins in the Prevention of Cardiovascular Disease and Cancer

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Methylation SNPs. Personalized Report for Jennifer Howard. = Optional Foundational Support. Yellow / Red = Highly Recommended Nutritional Support

Biology 2C03: Genetics What is a Gene?

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

2 International Conference on Predictive, Preventive and Personalized Medicine and Molecular Diagnostics

A Risk/Benefit Approach to Assess Nutrient Intake: Do we Need a New DRI?

Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor

Methylation. Taking the guesswork out of diagnosis. Proper functioning of the methylation cycle helps to reduce the risk of:

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

The role of vitamin E (tocopherol) supplementation in the prevention

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Controversies in Preventative Cardiology

BIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2014

From Genetic Testing to Personalized Approach in Patients Dr. Amirova Т.О. Prof. Bernard WEBER

Nutrigenetics and Nutrigenomics in Clinical Research and Practice

Zinc: Issues and Update. Craig Boreiko, Ph.D. Ottawa May 2008

Statins in the elderly : Is there a rationale?

The benefits of whole grain

D. Vitamin K -- Group of naphthoquinones having antihemorrhagic activity.

PHASE I Detoxification: The First Line of Defense

The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting

Nutrigenomics: Do our genes determine what we should eat?

Advanced Methylation Detoxification Profile

Dyslipidemia in women: Who should be treated and how?

BPK 110 Human Nutrition: Current Concepts

A loss-of-function variant in CETP and risk of CVD in Chinese adults

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

Understanding the potential of nutrigenomics/personalised nutrition to treat inflammation / CVD'

STROKE & DIETARY INFLUENCES ON COGNITION IN AGING

VDR GENE (Vitamin D Receptor)

Fasting or non fasting?

Nutraceuticals and Cardiovascular Disease: Are we fishing?

The health benefits of shellfish: What should we be promoting? Professor Bruce Griffin Nutrition Division Faculty of Health & Medical Sciences

The Interaction of Cigarette Smoking and Antioxidants. Part I: Diet and Carotenoids

LATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?

! These tests are not 100% accurate! Positive findings indicates predisposition only.! Results should not be interpreted as diagnostic with treatment

Macrovascular Disease in Diabetes

Use of DRIs at the U.S. Food and Drug Administration

Examining the relationship between beverage intake and cardiovascular health. Ian Macdonald University of Nottingham UK

dna oestrogen GENOTYPE REPORT Patient Name: Date of Birth: Sample Number: Referring Practitioner: Date Reported:

TPN and lipid. RCT of 57 patients. TPN with lipid vs TPN without lipid. TPN associated with increased infectious complications

Plant sterols/stanols for cholesterol lowering and prevention of cardiovascular disease

Appendix 1 Characteristics of Trials Included in the Final Meta-Analysis (n = 50) [posted as supplied by author] Duration of Supplementa

How to Reduce CVD Complications in Diabetes?

Atherosclerotic cardiovascular disease (CVD) involving. Vitamin Supplementation and Cardiovascular Disease CLINICAL REVIEW. William T.

KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy. Original Policy Date

Dairy Intake and Risk Factors for Chronic Disease

Correlations between the COMT gene rs4680 polymorphism and susceptibility to ovarian cancer

Prospective Natural-History Study of Coronary Atherosclerosis

Forebyggelse af metabolisk syndrom vha. mejeriprodukter

Preventive Participatory

WHOLE GRAIN INTAKE AND CARDIOVASCULAR DISEASE AND WHOLE GRAIN INTAKE AND DIABETES A REVIEW EXECUTIVE SUMMARY. November, 2008

Bench to Bedside PCSK9 Children are Different

What should I eat? I am so confused. Jennifer Lyon DO

Diabetic Dyslipidemia

Transcription:

Vitamin E and gene interactions Manfred Eggersdorfer, PhD Professor for Healthy Ageing Nutrition Science & Advocacy Bernd Mussler, PhD DSM Nutritional Products, Kaiseraugst, Switzerland London, November 19, 2014

Outline One size does not fit all: role of polymorphism Vitamin E is an established essential micronutrient, as defined in daily intake requirements, which has to be provided to the human body on a regular basis Emerging science suggests vitamin E to convey health benefits which are not addressed / covered by the daily requirements: Vitamin E & haptoglobin 2-2 Vitamin E & Catechol-O-Methyltransferase (COMT) variant rs4680 What is the prudent way forward to benefit human health by vitamin E?

FOR INTERNAL USE ONLY Today s nutrition: One size does not fit all. Not everyone responds similarly to food: People are different by polymorphisms

FOR INTERNAL USE ONLY Nutrigenomics will help to understand individual requirements The science of nutrigenomics seeks to provide a molecular understanding for how common dietary ingredients (i.e., nutrients) affect health by altering the expression and/or conformational structures of an individual s genetic makeup. Turning on and off your genes that control diseases!

FOR INTERNAL USE ONLY DNA is not your destiny

FOR INTERNAL USE ONLY Focus of the talk will be on vitamin E and out of the many nutrient gene interaction on two relevant once on which new science demonstrate health benefits Page 5

Vitamin E a chain-breaking antioxidant Vitamin E is a powerful chain-breaking antioxidant. Once oxidized, it can be regenerated by vitamin C. Due to its lipophilic nature, vitamin E localizes to lipid compartments, such as cell membranes (prevention of peroxidation of lipids and oxidation of proteins). Furthermore, vitamin E depletion and repletion affects gene expression in vitro in cells and in vivo in animal models, indicating broader effects than just protection from oxidation. Incorporation of vitamin E into cellular membranes can alter the activity of membraneassociated proteins and thereby changes signal transduction pathways. EFSA Health Claim in 2011: Vitamin E contributes to the protection of cells from oxidative stress Page 6

Nutrient requirements/recommended intakes Dietary reference values for nutrient intake are: Science-based Dependent on the existing data available Country or institution specific Potentially politically driven Reflect eating cultures Page 7

Current RDAs for vitamin E are based on markers of cell membrane integrity 1. Lysis of red blood cells 2. PUFA intake Lysis of erythrocytes are associated with decreases erythrocyte survival (which can be corrected by vitamin E supplementation) From research in a limited number of people, reported in the seventies a vitamin E serum level of 12 µmol/l was derived to prevent hemolysis To achieve a serum level of 12 µmol/l α-tocopherol an intake of 12 mg vitamin E is required 12 mg vitamin E is the intake to meet the requirements of 50% of the population (EAR) and 15 mg vitamin E will suffice to meet the needs of 97% of the population (RDA) Vitamin E requirements vary from 15 to 25 mg/day or more depending on PUFA intake Additional vitamin E needs should become part of RDA A higher intake of nutrients beyond nutritional requirements may provide additional benefits in defined groups RDA = Recommended Dietary Allowance Page 8 EAR = Estimated Average Requirement Institute of Medicine 2000

People are different,..!

and, emerging science provides new insights! There may be different needs, which can not be covered by the RDA approach In addition, we have a better understanding about the human genome There is evidence that the genotype can be key to a response of a given nutrient i.e., 10-20 mio Single Nucleotide Polymorphisms (SNP) believed to exist (ca 4 mio known) Two examples where the genotype can make a significant difference in human nutrition will be highlighted: Vitamin E & haptoglobin 2-2 Vitamin E & COMT variant rs4680 Page

Epidemiological evidence for vitamin E benefits Lower plasma level of vitamin E has been reported in type 2 diabetic subjects compared to controls. Prospective epidemiological studies demonstrate that high serum vitamin E was associated with decreased risk of type 2 diabetes. Evidence from various observational human studies indicated that vitamin E has beneficial effects on the cardiovascular system. Major coronary heart disease risk in women (after Knekt et al. 2004) At least five studies reported that increased consumption of vitamin E is associated with decreased risk for heart attack or death from cardiovascular disease. It was therefore hypothesized that vitamin E supplementation could reduce the risk for cardiovascular events. Favors high vitamin E Favors low vitamin E Page 11 Salonen et al. (1995) Maxwell et al. (1997)

However, most RCTs find no vitamin E benefits for cardiovascular health Several randomized clinical trials have been performed to examine the efficacy of vitamin E in improving human health. Surprisingly, the results from the trials did not detect a consistent benefit of vitamin E supplementation on cardiovascular health. Meta-Analysis of the effect of Vitamin E on Myocardial Infarction, Stroke, or Death from Cardiovascular Causes in large trials (modified from Yusuf et al. 2000) Study Dose Duration Cases ATBC 50 5yr 3859 CHAOS >400 1.3 105 GISSI 300 3.5 1155 HOPE 400 4.5 1511 Total 6630 Relative Risk 0.97 (0.92-1.02) 0.6 0.8 1.0 1.2 1.4 Favors vitamin E Favors placebo Page 12

FOR INTERNAL USE ONLY Vitamin E genotype matters! Several randomized clinical trials supplementing vitamin E failed to corroborate the epidemiological findings However, new research provides an insight into the apparent disagreement While no effects are observed in the general population; specific sub-populations with specific genetic make-up may profit from vitamin E Page

Vitamin E reduces cardiovascular events in diabetics and Hp 2-2 genotype Haptoglobin (Hp) is a protein that scavenges free hemoglobin in the blood. The Hp gene exists in two variants, the Hp1 and the Hp2 variant. In Western societies, 36% have haptoglobin genotype 2-2 (Hp 2-2) Diabetic individuals with Hp 2-2 have a marked increased oxidative stress Increased risk for cardiovascular events has been linked to Hp 2-2 genotype in diabetics. Vitamin E supplementation at a dose of 400 mg reduces and normalizes the risk for cardiovascular events in diabetics with Hp 2-2 Page 14

Findings from the ICARE Study are supported by results from other large-scale RCTs N = 2545 women and 6996 men 55+ yrs, CVD or diabetes + one other risk factor, 400 IU/d vitamin E or ACE-inhibitor or placebo for 4.5 years, composite endpoint Vitamin E had no apparent effect on cardiovascular outcomes Findings from the ICARE Study were confirmed in a post-hoc retrospective subgroup analysis of the HOPE and WHS study: Risk for cardiovascular events (CV death and nonfatal myocardial infarction) was significantly reduced only in the diabetics carrying the Hp 2-2 gene Page 15 Yusuf et al. (2000) Levy et al. (2004) Blum (2010) Vardi et al. (2012)

Proposed vitamin E function in diabetic Hp 2-2 individuals Haptoglobin binds and inhibits the oxidative activity of free hemoglobin (Hb), and targets it for clearance from the blood. The Haptoglobin 2 protein forms aggregates which affects its function. Hemoglobin is not cleared as efficiently. Furthermore, Hb-Hp2-2 complex binds to HDL, oxidizes proteins and lipids in HDL and renders HDL dysfunctional and prothrombic. Vitamin E protects lipids and proteins in HDL from oxidation Protection by vitamin E Page 16 Asleh et al. (2008)

Diabetes is a huge and growing public health problem 1. At least 1 in 10 deaths among adults is attributable to diabetes 2. Diabetes deaths are projected to double between 2005 and 2030 3. >80% of diabetes deaths occur in low- and middle-income countries Page 17 IDF Diabetes Atlas, 6 th ed. (2013)

Genetic variants of the Catechol-O-Methyltransferase Modify the Risk of Cardiovascular Diseases (Kathryn T. Hall et al, 2014, Arterioscler Thromb Vasc Biol) COMT degrades catecholamines by catalyzing the transfer of a methyl group donated by S- adenosyl methionine onto catechol moieties, resulting in their deactivation. The COMT genetic variant rs4680 (val158met) is an extensively studied single nucleotide polymorphism (SNP) that encodes a valine-tomethionine substitution This functional polymorphism results in the methionine variant having a 3- to 4-fold lower enzymatic activity than the valine variant WGHS* participants had a 34% lower risk for the primary outcome ( major CVD) with each additional valine allele in the COMT (val158met) SNP 18 * WGHS: Women s genome health study

Genetic variants of the Catechol-O-Methyltransferase Modify the Treatment Effect of Vitamin E on Cardiovascular Diseases (Kathryn T. Hall et al, 2014, Arterioscler Thromb Vasc Biol) Vitamin E (vs placebo) had a 47% risk reduction for major CVD in the participants carrying the homozygous methionine allele of this COMT polymorphism The authors conclude: the lack of an overall effect of vitamin E on CVD risk in the original WGHS* report does not preclude the possibility that subgroups defined on the basis of genetic strata experience benefit This may provide insights in the conflicting observations and overall null findings in CVD trials for vitamin E * WGHS: Page 19 Women s genome health study

FOR INTERNAL USE ONLY Conclusions Today s nutrition: One size does not fit all The anti-oxidative function of vitamin E is well established and is the basis on which the daily intake recommendations (which should be achieved by the diet) for vitamin E have been developed Emerging evidence supports the concept for a dual role of vitamin E in human health, which is at intakes / doses exceeding the RDA by a multiple Such pharmacological benefits of vitamin E are conceivable (which can typically not been achieved by a diet) for Diabetes CVD pts carrying a particular genotype Emerging science supporting a dual role for vitamin E in human health is encouraging and further research is recommended to better understand the implications of nutrient gene interaction on human health Page 20